Literature DB >> 17900104

Proteomic identification of the cerebral cavernous malformation signaling complex.

Thomas L Hilder1, Michael H Malone, Sompop Bencharit, John Colicelli, Timothy A Haystead, Gary L Johnson, Christine C Wu.   

Abstract

Cerebral cavernous malformations (CCM) are sporadic or inherited vascular lesions of the central nervous system characterized by dilated, thin-walled, leaky vessels. Linkage studies have mapped autosomal dominant mutations to three loci: ccm1 (KRIT1), ccm2 (OSM), and ccm3 (PDCD10). All three proteins appear to be scaffolds or adaptor proteins, as no enzymatic function can be attributed to them. Our previous results demonstrated that OSM is a scaffold for the assembly of the GTPase Rac and the MAPK kinase kinase MEKK3, for the hyperosmotic stress-dependent activation of p38 MAPK. Herein, we show that the three CCM proteins are members of a larger signaling complex. To define this complex, epitope-tagged wild type OSM or OSM harboring the mutation of F217-->A, which renders the OSM phosphotyrosine binding (PTB) domain unable to bind KRIT1, were stably introduced into RAW264.7 mouse macrophages. FLAG-OSM or FLAG-OSMF217A and the associated complex members were purified by immunoprecipitation using anti-FLAG antibody. OSM binding partners were identified by gel-based methods combined with electrospray ionization-MS or by multidimensional protein identification technology (MudPIT). Previously identified proteins that associate with OSM including KRIT1, MEKK3, Rac, and the KRIT1-binding protein ICAP-1 were found in the immunoprecipitates. In addition, we show for the first time that PDCD10 binds to OSM and is found in cellular CCM complexes. Other prominent proteins that bound the CCM complex include EF1A1, RIN2, and tubulin, with each interaction disrupted with the OSMF217A mutant protein. We further show that PDCD10 binds phosphatidylinositol di- and triphosphates and OSM binds phosphatidylinositol monophosphates. The findings define the targeting of the CCM complex to membranes and to proteins regulating trafficking and the cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900104     DOI: 10.1021/pr0704276

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  75 in total

1.  Ccm1 regulates microvascular morphogenesis during angiogenesis.

Authors:  Huiling Liu; Daniele Rigamonti; Ahmed Badr; Jun Zhang
Journal:  J Vasc Res       Date:  2010-10-07       Impact factor: 1.934

Review 2.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

3.  Systems biology and proteomic analysis of cerebral cavernous malformation.

Authors:  Alexander R Edelmann; Sarah Schwartz-Baxter; Christopher F Dibble; Warren C Byrd; Jim Carlson; Ivandario Saldarriaga; Sompop Bencharit
Journal:  Expert Rev Proteomics       Date:  2014-03-31       Impact factor: 3.940

Review 4.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

5.  PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Authors:  Svetlana M Stamatovic; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic
Journal:  Acta Neuropathol       Date:  2015-09-18       Impact factor: 17.088

6.  Expression of CCM2 and CCM3 during mouse gonadogenesis.

Authors:  Aylin Yaba; N Ece Gungor Ordueri; Gamze Tanriover; Pinar Sahin; Necdet Demir; Ciler Celik-Ozenci
Journal:  J Assist Reprod Genet       Date:  2015-09-19       Impact factor: 3.412

Review 7.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

8.  ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway.

Authors:  Jonathan N Rosen; Vanessa M Sogah; Lillian Y Ye; John D Mably
Journal:  Dev Biol       Date:  2013-01-15       Impact factor: 3.582

Review 9.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

10.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.